Lung Cells on a Chip Inhibit Tuberculosis Growth

A new approach to studying tuberculosis (TB) – a “lung-on-a-chip” that mimics the breathing human lung – is showing promise in inhibiting the growth of the bacteria that causes the disease. The technology, detailed in Medscape Medical News, utilizes four types of lung cells, including crucial immune cells, functioning together in a microengineered environment.

Understanding Tuberculosis and the Challenge of Research

Tuberculosis, an infectious disease typically affecting the lungs, remains a significant global health concern. According to the World Health Organization, an estimated 10.6 million people fell ill with TB in 2022, and 1.3 million died. The bacteria, Mycobacterium tuberculosis (Mtb), is spread through the air when people with active TB cough, sneeze, or otherwise transmit respiratory fluids. Traditional TB research relies heavily on animal models and in vitro studies – experiments conducted outside of a living organism – both of which have limitations in accurately replicating the complex environment of the human lung. Animal models don’t always perfectly mimic human disease, and traditional cell cultures lack the mechanical and physiological cues present in a living lung.

The lung-on-a-chip technology aims to bridge this gap. It’s a microfluidic device that contains living cells arranged to simulate the structure and function of lung tissue. Crucially, this new iteration incorporates the mechanical stretching and relaxation that occurs with each breath – a factor previously missing from many lab-based TB studies. This dynamic environment is thought to be critical for understanding how Mtb interacts with the lung and how the immune system responds.

How the ‘Breathing’ Lung-on-Chip Works

The chip itself is a small, clear device containing tiny channels lined with human lung cells. These cells include alveolar epithelial cells (which form the air sacs in the lungs), endothelial cells (lining blood vessels), and importantly, immune cells like macrophages. Macrophages are a type of white blood cell that engulfs and destroys pathogens, playing a key role in the body’s defense against TB. The chip is designed to flex rhythmically, mimicking the expansion and contraction of the lungs during breathing. Researchers can then introduce Mtb to the chip and observe how the bacteria behave in this simulated lung environment.

Initial findings, as reported by Medscape, suggest that this dynamic environment inhibits the growth of TB bacteria. The precise mechanisms behind this inhibition are still being investigated, but researchers believe it may be related to enhanced immune cell function and altered bacterial behavior in response to the mechanical forces of breathing. The clinical presentation of pulmonary TB often includes abnormal breath sounds, particularly in the upper lobes of the lungs, and this chip aims to replicate those conditions for study.

What So for TB Research and Treatment

This lung-on-a-chip technology isn’t intended to be a direct replacement for traditional research methods, but rather a complementary tool. It offers several potential advantages. First, it provides a more physiologically relevant model for studying TB, potentially leading to a better understanding of the disease process. Second, it can be used to screen potential new drugs and therapies more efficiently and effectively. Because the chip uses human cells, it may be more predictive of how a drug will perform in humans than animal models. Third, it can help researchers investigate the complex interplay between Mtb and the host immune system.

However, it’s important to acknowledge the limitations of this technology. A lung-on-a-chip is still a simplified model of the human lung. It doesn’t capture the full complexity of the organ, including its intricate vascular network, lymphatic system, and interactions with other parts of the body. The chip also doesn’t fully replicate the immune deficiencies or co-morbidities (like HIV) that can increase a person’s risk of developing TB. Findings from the chip need to be validated in more complex models and ultimately in clinical trials.

Pulmonary TB: A Closer Appear at the Disease Process

When Mtb enters the lungs, it’s typically inhaled into the alveoli – the tiny air sacs where oxygen and carbon dioxide exchange takes place. As Medscape explains, the bacteria are then taken up by macrophages. In a healthy immune system, macrophages are able to kill the bacteria. However, Mtb has evolved mechanisms to evade destruction by macrophages, allowing it to persist and multiply within these cells. This can lead to the formation of granulomas – clusters of immune cells that attempt to contain the infection. If the immune system is unable to control the infection, the bacteria can spread to other parts of the lungs and even to other organs.

The development of TB can be insidious, with many people infected but not developing active disease. This represents known as latent TB infection. People with latent TB infection are not contagious and do not have symptoms, but they are at risk of developing active TB later in life, especially if their immune system is weakened.

What Comes Next: Refining the Model and Exploring New Therapies

Researchers are now focused on refining the lung-on-a-chip model to make it even more realistic. This includes incorporating additional cell types, such as lymphatic endothelial cells, and developing more sophisticated methods for simulating the mechanical forces of breathing. They are also using the chip to screen a library of existing drugs to identify potential repurposing candidates for TB treatment. The technology could be used to personalize TB treatment by testing a patient’s own cells on the chip to determine which drugs are most likely to be effective.

The development of new tools like the “breathing” lung-on-chip represents a significant step forward in TB research. Even as challenges remain, this technology holds the potential to accelerate the discovery of new and more effective ways to prevent and treat this devastating disease. For the latest official guidance on tuberculosis, individuals should consult resources from organizations like the World Health Organization and their local public health authorities.